Abstract
Introduction: Until recently, there have been limited options for treatment of metastatic neuro endocrine tumors (NETs). Real life experience with newly developed targeted therapies for this condition is limited outside large referral centers.
Case: Here we describe a 43 year old patient with metastatic NET of intestinal origin. The management of this patient illustrates a number of real life practical issues including effect of treatment interruption, secondary resistance to somatostatin analogues, availability and toxicity of new targeted agents, multiple lines of sequential treatment and local availability of specific investigations. This patient is enjoying a long progression free survival (29+ months) on a combination of Everolimus and Octreotide-LAR with a survival of 43+ months from diagnosis of metastatic disease.
Conclusion: Patient with metastatic NETs can benefit from newly developed targeted therapies. However, they are best managed by multi-disciplinary teams in referral centers to guarantee adequate experience and specialist resources.
Keywords: Neuroendocrine, targeted therapy, Octreotide-LAR, Everolimus, Sunitinib, multi-disciplinary.
Current Cancer Therapy Reviews
Title:Metastatic Gastro-intestinal Neuroendocrine Tumors: A Case Report of Real Life Management Challenges and Success
Volume: 9 Issue: 3
Author(s): Jamal Zekri and Zahid Amin Khan
Affiliation:
Keywords: Neuroendocrine, targeted therapy, Octreotide-LAR, Everolimus, Sunitinib, multi-disciplinary.
Abstract: Introduction: Until recently, there have been limited options for treatment of metastatic neuro endocrine tumors (NETs). Real life experience with newly developed targeted therapies for this condition is limited outside large referral centers.
Case: Here we describe a 43 year old patient with metastatic NET of intestinal origin. The management of this patient illustrates a number of real life practical issues including effect of treatment interruption, secondary resistance to somatostatin analogues, availability and toxicity of new targeted agents, multiple lines of sequential treatment and local availability of specific investigations. This patient is enjoying a long progression free survival (29+ months) on a combination of Everolimus and Octreotide-LAR with a survival of 43+ months from diagnosis of metastatic disease.
Conclusion: Patient with metastatic NETs can benefit from newly developed targeted therapies. However, they are best managed by multi-disciplinary teams in referral centers to guarantee adequate experience and specialist resources.
Export Options
About this article
Cite this article as:
Zekri Jamal and Khan Amin Zahid, Metastatic Gastro-intestinal Neuroendocrine Tumors: A Case Report of Real Life Management Challenges and Success, Current Cancer Therapy Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573394709666131108210254
DOI https://dx.doi.org/10.2174/1573394709666131108210254 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protective Role of Diabetes Mellitus on Abdominal Aortic Aneurysm Pathogenesis: Myth or Reality?
Current Vascular Pharmacology Aliskiren: A Novel Renin Inhibitor for Hypertension
Current Drug Therapy Milk Fat Globule Epidermal Growth Factor VIII Signaling in Arterial Wall Remodeling
Current Vascular Pharmacology The Relationship between Inflammatory and Oxidative Stress Biomarkers, Atherosclerosis and Rheumatic Diseases
Current Pharmaceutical Design Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets A Pilot Study on Wet Age Related Macular Degeneration in Chennai and Some Parts of Kerala
Applied Clinical Research, Clinical Trials and Regulatory Affairs Impact of Clinical Audit on Adherence to the Guidelines Directed Medical Therapy in Patients Admitted with Heart Failure
Current Drug Safety Heart Rate Variability Indexes in Dementia: A Systematic Review with a Quantitative Analysis
Current Alzheimer Research Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors
Current Vascular Pharmacology Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
Current Vascular Pharmacology Mild Cognitive Impairment: Advantages of a Comprehensive Neuropsychological Assessment
Current Alzheimer Research Ambulatory Blood Pressure Monitoring in Prehypertensive Subjects
Cardiovascular & Hematological Disorders-Drug Targets Opioid Growth Factor and its Derivatives as Potential Non-toxic Multifunctional Anticancer and Analgesic Compounds
Current Medicinal Chemistry Cell Adhesion Molecules as Pharmaceutical Target in Atherosclerosis
Mini-Reviews in Medicinal Chemistry Vasopeptidase Inhibition for Blood Pressure Control: Emerging Experience
Current Pharmaceutical Design Critical Determinants of Cardiovascular Risk in Rheumatoid Arthritis
Current Pharmaceutical Design Editorial [Hot Topic: The Plasminogen Activation System in Pathology: Use in Prognosis and Therapy (Guest Editor: Marie Ranson)]
Current Drug Targets Dampening the Progression of Dementia
Current Neurovascular Research 6-Chloro-7-methyl-3', 4'-dimethoxyflavone – a Potent Selective COX-2 Inhibitor
Medicinal Chemistry Laparoscopic Surgery for Pheochromocytoma and Paraganglioma Removal: A Retrospective Analysis of Anaesthetic Management
Current Hypertension Reviews